• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

liver disease

three triple doors opportunity cracked open ajar
Biotech

GSK picks 1st biotech partners under $7B Flagship pact

Notably, Profound and Quotient are the two biotechs Pfizer has also chosen to work with in a separate VC-pharma collaboration.
Gabrielle Masson Nov 20, 2025 6:30am
decision path change of plans arrows business decision

Aldeyra drops and swaps RASP assets in response to data

Oct 28, 2025 9:10am
Fiji Cloudbreak wave ocean surf

Wave reports AATD win, but investors lukewarm

Sep 3, 2025 3:00pm
liver disease fibrosis NASH NAFLD cancer cirrhosis liver

Zydus' phase 3 win tees up filing to challenge Gilead and Ipsen

Aug 29, 2025 10:59am
liver

FDA considers new liver trial endpoint, sending MASH shares up

Aug 28, 2025 11:25am
GlaxoSmithKline

GSK pays $1.2B upfront for Boston's lead liver disease drug

May 14, 2025 2:53am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings